Found: 62
Select item for more details and to access through your institution.
Distribution and prognosis of uncommon metastases from non-small cell lung cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 2, p. 477, doi. 10.1007/s10637-020-01010-4
- By:
- Publication type:
- Article
Clinicopathological features and resistance mechanisms in HIP1‐ALK‐rearranged lung cancer: A multicenter study.
- Published in:
- Genes, Chromosomes & Cancer, 2022, v. 61, n. 4, p. 177, doi. 10.1002/gcc.23005
- By:
- Publication type:
- Article
Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients.
- Published in:
- Supportive Care in Cancer, 2015, v. 23, n. 3, p. 635, doi. 10.1007/s00520-014-2405-y
- By:
- Publication type:
- Article
Chemical shift magnetic resonance imaging for distinguishing minimal-fat renal angiomyolipoma from renal cell carcinoma: a meta-analysis.
- Published in:
- 2018
- By:
- Publication type:
- journal article
PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepitheliomalike carcinoma.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.951817
- By:
- Publication type:
- Article
Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma‐like carcinoma.
- Published in:
- Clinical & Translational Immunology, 2024, v. 13, n. 6, p. 1, doi. 10.1002/cti2.1515
- By:
- Publication type:
- Article
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors.
- Published in:
- Experimental Hematology & Oncology, 2021, v. 10, n. 1, p. 1, doi. 10.1186/s40164-021-00245-y
- By:
- Publication type:
- Article
Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. N.PAG, doi. 10.3389/fonc.2020.596937
- By:
- Publication type:
- Article
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231167818
- By:
- Publication type:
- Article
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 10, p. 1679, doi. 10.1038/s41416-024-02615-9
- By:
- Publication type:
- Article
Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.
- Published in:
- Journal of Translational Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12967-024-05135-5
- By:
- Publication type:
- Article
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial.
- Published in:
- Signal Transduction & Targeted Therapy, 2023, v. 8, n. 1, p. 1, doi. 10.1038/s41392-022-01286-3
- By:
- Publication type:
- Article
Genotyping of RB1 status identifies two distinct subtypes in EGFR‐mutant lung cancers with SCLC transformation.
- Published in:
- Clinical & Translational Medicine, 2024, v. 14, n. 5, p. 1, doi. 10.1002/ctm2.1683
- By:
- Publication type:
- Article
Concomitant genetic alterations having greater impact on the clinical benefit of EGFR‐TKIs in EGFR‐mutant advanced NSCLC than BIM deletion polymorphism.
- Published in:
- Clinical & Translational Medicine, 2020, v. 10, n. 1, p. 337, doi. 10.1002/ctm2.12
- By:
- Publication type:
- Article
Familial association of lung cancer with liver cancer in first-degree relatives.
- Published in:
- Cancer Management & Research, 2019, v. 11, p. 5813, doi. 10.2147/CMAR.S199462
- By:
- Publication type:
- Article
Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy.
- Published in:
- Molecular Oncology, 2023, v. 17, n. 8, p. 1581, doi. 10.1002/1878-0261.13439
- By:
- Publication type:
- Article
Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases.
- Published in:
- International Journal of Clinical Oncology, 2020, v. 25, n. 2, p. 267, doi. 10.1007/s10147-019-01552-5
- By:
- Publication type:
- Article
Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 7, p. 2987, doi. 10.1007/s00432-022-04188-7
- By:
- Publication type:
- Article
Lung Cancer Treatment Disparities in China: A Question in Need of an Answer.
- Published in:
- Oncologist, 2014, v. 19, n. 10, p. 1084, doi. 10.1634/theoncologist.2014-0007
- By:
- Publication type:
- Article
EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas.
- Published in:
- Oncologist, 2012, v. 17, n. 7, p. 978, doi. 10.1634/theoncologist.2011-0385
- By:
- Publication type:
- Article
Mixed response to the first‐line treatment of KRAS G12C inhibitor, sotorasib, in non‐small cell lung cancer: A brief report.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules.
- Published in:
- Journal of Extracellular Vesicles, 2019, v. 8, n. 1, p. 1, doi. 10.1080/20013078.2019.1663666
- By:
- Publication type:
- Article
Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
- Published in:
- Clinical Lung Cancer, 2022, v. 23, n. 2, p. 135, doi. 10.1016/j.cllc.2021.09.002
- By:
- Publication type:
- Article
Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).
- Published in:
- 2021
- By:
- Publication type:
- journal article
Soluble c-Met Levels Correlated With Tissue c-Met Protein Expression in Patients With Advanced Non-Small-Cell Lung Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp‐ untreated patients with advanced non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 11, p. 1619, doi. 10.1111/1759-7714.14429
- By:
- Publication type:
- Article
Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non‐small cell lung cancers.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 9, p. 1333, doi. 10.1111/1759-7714.14393
- By:
- Publication type:
- Article
High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 19, p. 2564, doi. 10.1111/1759-7714.14137
- By:
- Publication type:
- Article
Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status.
- Published in:
- PLoS ONE, 2012, v. 7, n. 6, p. 1, doi. 10.1371/journal.pone.0040109
- By:
- Publication type:
- Article
Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study.
- Published in:
- World Journal of Surgical Oncology, 2017, v. 15, p. 1, doi. 10.1186/s12957-016-1064-5
- By:
- Publication type:
- Article
Association of Cerebrospinal Fluid Tumor DNA Genotyping With Survival Among Patients With Lung Adenocarcinoma and Central Nervous System Metastases.
- Published in:
- JAMA Network Open, 2020, v. 3, n. 8, p. e209077, doi. 10.1001/jamanetworkopen.2020.9077
- By:
- Publication type:
- Article
Polymorphism of rs9387478 correlates with overall survival in female nonsmoking patients with lung cancer.
- Published in:
- International Journal of Biological Markers, 2016, v. 31, n. 2, p. e144, doi. 10.5301/jbm.5000180
- By:
- Publication type:
- Article
Single nucleotide polymorphisms in VTI1A gene contribute to the susceptibility of Chinese population to non-small cell lung cancer.
- Published in:
- International Journal of Biological Markers, 2015, v. 30, n. 3, p. e286, doi. 10.5301/jbm.5000140
- By:
- Publication type:
- Article
Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations.
- Published in:
- International Journal of Biological Markers, 2013, v. 28, n. 3, p. 249, doi. 10.5301/JBM.5000039
- By:
- Publication type:
- Article
Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients.
- Published in:
- Biomarker Research, 2020, v. 8, n. 1, p. 1, doi. 10.1186/s40364-020-00199-z
- By:
- Publication type:
- Article
Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy.
- Published in:
- Medical Oncology, 2012, v. 29, n. 2, p. 627, doi. 10.1007/s12032-011-9924-x
- By:
- Publication type:
- Article
Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2020, v. 11, n. 6, p. 1512, doi. 10.1111/1759-7714.13419
- By:
- Publication type:
- Article
Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2018, v. 9, n. 9, p. 1093, doi. 10.1111/1759-7714.12791
- By:
- Publication type:
- Article
Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation.
- Published in:
- Thoracic Cancer, 2017, v. 8, n. 1, p. 51, doi. 10.1111/1759-7714.12382
- By:
- Publication type:
- Article
Feasibility of computed tomography-guided core needle biopsy in producing state-of-the-art clinical management in Chinese lung cancer.
- Published in:
- Thoracic Cancer, 2014, v. 5, n. 2, p. 155, doi. 10.1111/1759-7714.12076
- By:
- Publication type:
- Article
KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2013, v. 20, n. 4, p. 1381, doi. 10.1245/s10434-012-2754-z
- By:
- Publication type:
- Article
A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 6, p. 1393, doi. 10.1007/s00262-021-03091-3
- By:
- Publication type:
- Article
Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 471, doi. 10.1007/s00262-017-2098-4
- By:
- Publication type:
- Article
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC.
- Published in:
- Cancers, 2023, v. 15, n. 1, p. 302, doi. 10.3390/cancers15010302
- By:
- Publication type:
- Article
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases.
- Published in:
- 2022
- By:
- Publication type:
- journal article